Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06841159RecruitingPhase 2
Personalized radiation plus immunotherapy and chemo for metastatic colorectal cancer
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
ShanghaiAges 18–75 - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15–99 - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Sacramento, CaliforniaAges 2 months+ - NCT06879041RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This study tests a new radioactive drug, [225Ac]-AZD2284, for men with prostate cancer that has spread and no longer responds to hormone therapy. The drug is designed to target cancer cells and deliver radiation directly to them, potentially slowing the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT07085442Recruiting
Audit of targeted lymph node biopsy for early breast cancer
This study looks at how well a special type of lymph node biopsy works for people with early breast cancer that has spread to a small number of lymph nodes. It aims to see if this approach is effective and safe, which may help guide future treatment decisions.
BurnleyAges 18 years+ - NCT07783282RecruitingPhase 1
How prostate cancer drugs affect a new medicine
This study looks at how a new medicine called fezolinetant is processed by the body when taken alongside common prostate cancer hormone treatments. It is an early-phase trial that helps researchers understand if there are any drug interactions, which could be important for future treatment options.
Plovdiv, Plovdiv ProvinceAges 50–75 - NCT07714018Recruiting
Comparing two weight loss programs for kidney cancer patients
This study tests two different weight loss programs to see which one helps prevent kidney cancer from growing in people with small kidney masses who are under active surveillance. It may help by improving overall health and potentially slowing cancer progression.
Buffalo, New YorkAges 18 years+ - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT07873450RecruitingPhase 1/Phase 2
Study of a new treatment for advanced cancers with c-MET protein
This study tests a new radioactive treatment for people with advanced solid tumors, such as certain lung, colon, head and neck, or bile duct cancers, that have stopped responding to standard treatments. The treatment targets a protein called c-MET found on cancer cells, aiming to deliver radiation directly to the tumor.
NedlandsAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Anchorage, AlaskaAges 18 years+ - NCT07649655RecruitingPhase 1
Combination therapy for left-sided colorectal cancer
This study tests a new experimental drug, EMB-01, combined with different chemotherapy regimens to treat left-sided colorectal cancer that has spread or cannot be removed. The goal is to see if this combination is safe and effective for people who have not responded to standard treatments or are new to certain chemotherapies.
Beijing, Beijing MunicipalityAges 18–74 - NCT07297667RecruitingPhase 1
CAR T-cell therapy for certain advanced solid tumors
This trial tests a new treatment called GCAR1, which uses your own immune cells (T-cells) to find and attack cancer cells that have a specific marker called GPNMB. It is for people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if this therapy can help shrink or control the tumor.
Calgary, AlbertaAges 15 years+ - NCT06391242RecruitingPhase 3
Comparing radiation treatments for painful bone metastases
This trial compares two types of radiation therapy—standard palliative radiation and a more targeted high-dose treatment (SBRT)—to see which better relieves pain from bone metastases that have spread outside the spine. It is for people with solid tumors who have a painful bone spot and are expected to live at least 6 months.
Calgary, AlbertaAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Birmingham, AlabamaAges 18 years+ - NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Huntsville, AlabamaAges 18 years+ - NCT07805954RecruitingPhase 3
New targeted pills for first-line metastatic pancreatic cancer
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
Phoenix, ArizonaAges 18 years+ - NCT07162506RecruitingPhase 2
Chemo-immunotherapy then surgery or radiation for esophageal cancer
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07448142RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo for advanced rectal cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called pucotenlimab, and chemotherapy for locally advanced rectal cancer that has not spread. The goal is to see if adding radiation helps shrink the tumor more effectively before surgery.
Guangzhou, GuanggongAges 18–75 - NCT06623396RecruitingPhase 1
Mesothelin-targeted CAR T cells for esophagogastric cancer or mesothelioma
This trial tests a new treatment that uses your own immune cells (T cells) engineered to find and attack cancer cells that have a protein called mesothelin on their surface. It is for people with advanced or recurrent esophagogastric cancer (cancer of the esophagus or stomach) or malignant peritoneal mesothelioma (a rare cancer of the lining of the abdomen). The treatment involves collecting your T cells, modifying them in a lab, and then giving them back to you after a short course of chemotherapy to help them work.
Basking Ridge, New JerseyAges 18 years+ - NCT07876154RecruitingPhase 2
Immunotherapy plus chemo before surgery for locally advanced cervical cancer
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
Xi'an, ShaanxiAges 18–70 - NCT07159204RecruitingPhase 2
A trial testing a chemo plus immunotherapy combo for biliary tract cancer
This trial tests a combination of a special form of chemotherapy (paclitaxel micelle) and an immunotherapy for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder) that has not responded to or stopped working after first treatment. The goal is to see if this combination can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–74 - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Phoenix, ArizonaAges 18 years+ - NCT05691517RecruitingPhase 1
Test drug CBX-12 in advanced cancers and monitor your response
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Bethesda, MarylandAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,580 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.